Intervention Review

Rosiglitazone for type 2 diabetes mellitus

  1. Bernd Richter1,*,
  2. Elizabeth Bandeira-Echtler1,
  3. Karla Bergerhoff1,
  4. Christine Clar2,
  5. Susanne H Ebrahim3

Editorial Group: Cochrane Metabolic and Endocrine Disorders Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 29 APR 2007

DOI: 10.1002/14651858.CD006063.pub2

Database Title

Additional Information

How to Cite

Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD006063. DOI: 10.1002/14651858.CD006063.pub2.

Author Information

  1. 1

    Universitaetsklinikum Duesseldorf, Heinrich-Heine University, Department of General Practice, Duesseldorf, Germany

  2. 2

    Cochrane Metabolic and Endocrine Disorders Group, Researcher in Systematic Reviews , Berlin, Germany

  3. 3

    Institute for Quality and Efficiency in Health Care, Cologne, Germany

*Bernd Richter, Department of General Practice, Universitaetsklinikum Duesseldorf, Heinrich-Heine University, PO Box 101007, Duesseldorf, 40001, Germany. richterb@uni-duesseldorf.de.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (60K)Standard (597K)Full (857K)

  1. Current Version

    Rosiglitazone for type 2 diabetes mellitus

    Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christine Clar and Susanne H Ebrahim

    Article first published online: 21 JAN 2009 | DOI: 10.1002/14651858.CD006063.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Rosiglitazone for type 2 diabetes mellitus

    B Richter, E Bandeira-Echtler, K Bergerhoff, C Clar and SH Ebrahim

    Article first published online: 18 APR 2007 | DOI: 10.1002/14651858.CD006063

View Full Article (HTML) Summary (60K)Standard (597K)Full (857K)